Opdualag™ (nivolumab and relatlimab-rmbw) is a prescription medicine used to treat adults and children 12 years of age or older with a type of skin cancer called melanoma that has spread or cannot be removed by surgery (advanced melanoma). It is not known if Opdualag is safe and effective when used in children younger than 12 years of age or older who weigh less than 88 pounds (40 kg), or in children younger than 12 years of age.
Pricing Information
Like many patients, knowing what you may pay for treatment can be a major concern. That’s why Bristol Myers Squibb (BMS) is committed to helping you understand your out-of-pocket (OOP) costs and possible resources that may help make them more affordable.
The information below may help you understand not only the list price of your medication but what your out-of-pocket (OOP) costs might be, based on your insurance coverage.
Opdualag is a combination of 2 immunotherapies available in a single vial of 240 mg nivolumab and 80 mg relatlimab per 20 mL,* with a list price of $15,120. Most patients will not pay this amount.†
*Opdualag is a premixed prescription medication of nivolumab and relatlimab in the same vial that is prepared and given as a single intravenous (IV) infusion by your healthcare team. Adult patients and pediatric patients 12 years of age or older who weigh at least 40 kg will receive 2 vials (480 mg nivolumab and 160 mg relatlimab) per treatment every 4 weeks.
†This price does not include the cost of administration or infusion center costs. This list price is current as of 01/01/2025.
The BMS Co-Pay Assistance program may help eligible commercially insured patients pay as little as $0 per infusion. BMS will cover the rest of the cost, up to $25,000 per year.
Depending on your specific Medicare benefits, you may pay 0-20% of the medication list price per infusion. You may have a supplemental insurance plan that may pay all or part of your Opdualag cost. Please check with your Medicare plan administrator for more details and to understand your specific costs.
You could pay $0-$20 per infusion (depending on state plan). To find out if you qualify for Medicaid, or to get more information about co-payments in your state, please use this link to visit the Medicaid website.
If you do not have insurance coverage for Opdualag, you can expect to pay the list price shown above per vial used. Patients without insurance are encouraged to call 1-800-861-0048, 8AM–8PM EST, Monday–Friday to explore potential options.
For additional information, the BMS Access Support® Program provides resources to help patients understand their insurance coverage and find information on sources of potential financial support.
Please visit BMS Access Support, or call BMS Access Support at 1-800-861-0048, 8AM–8PM EST, Monday–Friday.
Important Safety Information
for Opdualag (nivolumab
and relatlimab-rmbw)
What is the most important information I should know about Opdualag?
Opdualag is a medicine that may treat a type of skin cancer called melanoma by working with your immune system. Opdualag can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or can lead to death. These problems may happen anytime during treatment or even after your treatment has ended. You may have more than one of these problems at the same time.
Call or see your healthcare provider right away if you develop any new or worse signs or symptoms, including:
- Lung problems: new or worsening cough; shortness of breath; chest pain
- Intestinal problems: diarrhea (loose stools) or more frequent bowel movements than usual; stools that are black, tarry, sticky, or have blood or mucus; severe stomach-area (abdominal) pain or tenderness
- Liver problems: yellowing of your skin or the whites of your eyes; severe nausea or vomiting; pain on the right side of your stomach area (abdomen); dark urine (tea colored); bleeding or bruising more easily than normal
- Hormone gland problems: headaches that will not go away or unusual headaches; eye sensitivity to light; eye problems; rapid heartbeat; increased sweating; extreme tiredness; weight gain or weight loss; feeling more hungry or thirsty than usual; urinating more often than usual; hair loss; feeling cold; constipation; your voice gets deeper; dizziness or fainting; changes in mood or behavior, such as decreased sex drive, irritability, or forgetfulness
- Kidney problems: decrease in your amount of urine; blood in your urine; swelling in your ankles; loss of appetite
- Skin problems: rash; itching; skin blistering or peeling; painful sores or ulcers in the mouth or nose, throat, or genital area
- Heart Problems: new or worse chest pain; irregular heartbeat or feel like your heart is racing; shortness of breath; tiredness; swelling in your ankles
Problems can also happen in other organs and tissues. These are not all of the signs and symptoms of immune system problems that can happen with Opdualag. Call or see your healthcare provider right away for any new or worsening signs or symptoms, which may include:
- Confusion; sleepiness; memory problems; changes in mood or behavior; stiff neck; balance problems; tingling or numbness of the arms or legs
- Double vision; blurry vision; sensitivity to light; eye pain; changes in eyesight
- Persistent or severe muscle pain or weakness; muscle cramps
- Low red blood cells; bruising
Getting medical help right away may help keep these problems from becoming more serious. Your healthcare team will check you for these problems during treatment with Opdualag. Your healthcare provider may treat you with corticosteroid or hormone replacement medicines. Your healthcare provider may also need to delay or completely stop your treatment with Opdualag if you have severe side effects.
Possible side effects of Opdualag
Opdualag can cause serious side effects, including:
- See “What is the most important information I should know about Opdualag?”
- Severe infusion reactions. Tell your healthcare provider or nurse right away if you get these symptoms during an infusion of Opdualag: chills or shaking; itching or rash; flushing; shortness of breath; dizziness; feel like passing out; fever; back or neck pain
- Complications of stem cell transplant that uses donor stem cells (allogeneic). These complications can be severe and can lead to death. These complications may happen if you underwent transplantation either before or after being treated with Opdualag. Your healthcare provider will monitor you for signs of complications if you have an allogeneic stem cell transplant.
The most common side effects of Opdualag include: muscle and bone pain; tiredness; decreased red blood cell and white blood cell counts; increased liver function test results; rash; itching, diarrhea; decreased salt (sodium) in your blood.
These are not all the possible side effects of Opdualag. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Before receiving Opdualag, tell your healthcare provider if you:
- have immune system problems such as Crohn’s disease, ulcerative colitis, or lupus
- have received an organ transplant
- have received or plan to receive a stem cell transplant that uses donor stem cells (allogeneic)
- have a condition that affects your nervous system, such as myasthenia gravis, or Guillain-Barré syndrome
- are pregnant or plan to become pregnant. Opdualag can harm your unborn baby
- your healthcare provider should do a pregnancy test before you start receiving Opdualag
- you should use an effective method of birth control during and for at least 5 months after the last dose of Opdualag. Talk to your healthcare provider about birth control methods that you can use during this time
- tell your healthcare provider right away if you become pregnant during treatment with Opdualag
- are breastfeeding or plan to breastfeed. It is not known if Opdualag passes into your breast milk. Do not breastfeed during treatment with Opdualag and for 5 months after the last dose of Opdualag
Females who are able to become pregnant:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
INDICATION:
Opdualag™ (nivolumab and relatlimab-rmbw) is a prescription medicine used to treat adults and children 12 years of age or older with a type of skin cancer called melanoma that has spread or cannot be removed by surgery (advanced melanoma). It is not known if Opdualag is safe and effective when used in children younger than 12 years of age or who weigh less than 88 pounds (40 kg), or in children younger than 12 years of age.
Please see U.S. Full Prescribing Information and Medication Guide for Opdualag.
© 2022 Bristol-Myers Squibb Company.
Opdualag™ is a trademark of Bristol-Myers Squibb Company.
BMS Access Support is a registered trademark of Bristol-Myers Squibb Company.
This site is intended for U.S. residents 18 years of age or older.
1425-US-2200117 04/22
You are now leaving this Bristol Myers Squibb site.
This internet site may provide links or references to other sites. Bristol Myers Squibb has no responsibility for the content of such other sites and is not liable for any damages or injury arising from that content. Any links to other sites are provided merely as a convenience to the users of this internet site.
Would you like to leave this site?